LymeNet Home LymeNet Home Page LymeNet Flash Discussion LymeNet Support Group Database LymeNet Literature Library LymeNet Legal Resources LymeNet Medical & Scientific Abstract Database LymeNet Newsletter Home Page LymeNet Recommended Books LymeNet Tick Pictures Search The LymeNet Site LymeNet Links LymeNet Frequently Asked Questions About The Lyme Disease Network LymeNet Menu

LymeNet on Facebook

LymeNet on Twitter




The Lyme Disease Network receives a commission from Amazon.com for each purchase originating from this site.

When purchasing from Amazon.com, please
click here first.

Thank you.

LymeNet Flash Discussion
Dedicated to the Bachmann Family

LymeNet needs your help:
LymeNet 2020 fund drive


The Lyme Disease Network is a non-profit organization funded by individual donations.

LymeNet Flash Post New Topic  New Poll  Post A Reply
my profile | directory login | register | search | faq | forum home

  next oldest topic   next newest topic
» LymeNet Flash » Questions and Discussion » Medical Questions » Cloning and characterization of Rhipicephalus and its effect as anti-tick vaccine.

 - UBBFriend: Email this page to someone!    
Author Topic: Cloning and characterization of Rhipicephalus and its effect as anti-tick vaccine.
Melanie Reber
Frequent Contributor (5K+ posts)
Member # 3707

Icon 2 posted      Profile for Melanie Reber   Author's Homepage         Edit/Delete Post   Reply With Quote 
Yamada S, Konnai S, Imamura S, Ito T, Onuma M, Ohashi K
Cloning and characterization of Rhipicephalus appendiculatus voraxinalpha and its effect as anti-tick vaccine. [JOURNAL ARTICLE]
Vaccine 2009 Aug 6.


Male tick-derived voraxinalpha and voraxinbeta, a pair of testicular proteins, are transferred to female via copulation to stimulate female blood feeding in the tick Amblyomma hebraeum (A. hebraeum). Immunized animals with recombinant (r-)voraxinalpha and voraxinbeta have been shown as highly resistant to the tick infestation.

In this study, we describe the cloning and characterization of voraxinalpha homologue from the tick Rhipicephalus appendiculatus (R. appendiculatus), the major vector for East Coast fever in Eastern Africa.

The sequence analysis of the R. appendiculatus voraxinalpha indicated that the deduced amino acid sequence had high similarity with voraxinalpha of the tick A. hebraeum and Dermacentor variabilis, suggesting that voraxinalpha is conserved in different tick genera.

Quantitative RT-PCR and Western blotting analysis showed that male voraxinalpha was predominantly expressed in testis and its expression was induced by blood feeding. R. appendiculatus voraxinalpha was not secreted into the host during tick feeding and was detected in mated female hemolymph as measured by Western blotting.

Preliminary vaccination of rabbits with r-voraxinalpha elicited the humoral immunity and conferred protective immunity against female ticks, resulting in the reduced fed weight. These results suggest that r-voraxinalpha could be a good candidate as anti-tick vaccine.

Posts: 7052 | From Colorado | Registered: Mar 2003  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code� is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | LymeNet home page | Privacy Statement

Powered by UBB.classic™ 6.7.3


The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:

The Lyme Disease Network of New Jersey
907 Pebble Creek Court, Pennington, NJ 08534 USA


| Flash Discussion | Support Groups | On-Line Library
Legal Resources | Medical Abstracts | Newsletter | Books
Pictures | Site Search | Links | Help/Questions
About LymeNet | Contact Us

© 1993-2020 The Lyme Disease Network of New Jersey, Inc.
All Rights Reserved.
Use of the LymeNet Site is subject to Terms and Conditions.